These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18401021)

  • 1. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.
    Lopez OL; Kuller LH; Mehta PD; Becker JT; Gach HM; Sweet RA; Chang YF; Tracy R; DeKosky ST
    Neurology; 2008 May; 70(19):1664-71. PubMed ID: 18401021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cystatin C and the risk of Alzheimer disease in elderly men.
    Sundelöf J; Arnlöv J; Ingelsson E; Sundström J; Basu S; Zethelius B; Larsson A; Irizarry MC; Giedraitis V; Rönnemaa E; Degerman-Gunnarsson M; Hyman BT; Basun H; Kilander L; Lannfelt L
    Neurology; 2008 Sep; 71(14):1072-9. PubMed ID: 18824671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease.
    Blasko I; Kemmler G; Jungwirth S; Wichart I; Krampla W; Weissgram S; Jellinger K; Tragl KH; Fischer P
    Am J Geriatr Psychiatry; 2010 Nov; 18(11):973-82. PubMed ID: 20808106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.
    Schupf N; Patel B; Pang D; Zigman WB; Silverman W; Mehta PD; Mayeux R
    Arch Neurol; 2007 Jul; 64(7):1007-13. PubMed ID: 17620492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study.
    Poljak A; Crawford JD; Smythe GA; Brodaty H; Slavin MJ; Kochan NA; Trollor JN; Wen W; Mather KA; Assareh AA; Ng PC; Sachdev PS
    Curr Alzheimer Res; 2016; 13(3):243-55. PubMed ID: 26679856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.
    Sundelöf J; Giedraitis V; Irizarry MC; Sundström J; Ingelsson E; Rönnemaa E; Arnlöv J; Gunnarsson MD; Hyman BT; Basun H; Ingelsson M; Lannfelt L; Kilander L
    Arch Neurol; 2008 Feb; 65(2):256-63. PubMed ID: 18268197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
    Gurol ME; Irizarry MC; Smith EE; Raju S; Diaz-Arrastia R; Bottiglieri T; Rosand J; Growdon JH; Greenberg SM
    Neurology; 2006 Jan; 66(1):23-9. PubMed ID: 16401840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
    Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
    Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele.
    Sun X; Chiu CC; Liebson E; Crivello NA; Wang L; Claunch J; Folstein M; Rosenberg I; Mwamburi DM; Peter I; Qiu WQ
    Alzheimer Dis Assoc Disord; 2009; 23(3):238-44. PubMed ID: 19812466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease.
    Waragai M; Yoshida M; Mizoi M; Saiki R; Kashiwagi K; Takagi K; Arai H; Tashiro J; Hashimoto M; Iwai N; Uemura K; Igarashi K
    J Alzheimers Dis; 2012; 32(1):33-41. PubMed ID: 22751175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.
    Xia W; Yang T; Shankar G; Smith IM; Shen Y; Walsh DM; Selkoe DJ
    Arch Neurol; 2009 Feb; 66(2):190-9. PubMed ID: 19204155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer's disease.
    Chiu MJ; Yang SY; Chen TF; Chieh JJ; Huang TZ; Yip PK; Yang HC; Cheng TW; Chen YF; Hua MS; Horng HE
    Curr Alzheimer Res; 2012 Dec; 9(10):1142-8. PubMed ID: 22950866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study.
    Shah NS; Vidal JS; Masaki K; Petrovitch H; Ross GW; Tilley C; DeMattos RB; Tracy RP; White LR; Launer LJ
    Hypertension; 2012 Apr; 59(4):780-6. PubMed ID: 22392902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
    Bos I; Vos S; Vandenberghe R; Scheltens P; Engelborghs S; Frisoni G; Molinuevo JL; Wallin A; Lleó A; Popp J; Martinez-Lage P; Baird A; Dobson R; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Bertram L; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Visser PJ
    Alzheimers Res Ther; 2018 Jul; 10(1):64. PubMed ID: 29980228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
    Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
    J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.